No studies have ever been performed on the metabolism of 2C-T-2 or 2C-T-7. The metabolism of the related drugs 2C-B and mescaline have been studied however, and based on this it is possible to construct hypothetical metabolic pathways for 2C-T-2 and 2C-T-7.
Studies of human volunteers given mescaline have found at least 11 metabolites excreted in urine, as well as mescaline itself, which makes up 60% of the excreted material. Another 30% of the original drug is excreted as 3,4,5-trimethoxyphenylacetic acid. Another 5% is excreted as the metabolite N-acetyl-beta-(3,4-dimethoxy-5-hydroxy)-phenethylamine. Several other trace metabolites, including N-acetylmescaline and 3,4-dimethoxy-5-hydroxyphenethylamine, are also excreted.
Studies with animals and in vitro studies have found that mescaline undergoes oxidative deamination. There is some question as to what enzyme does this however, with some researchers suspecting monoamine oxidase, some suspecting diamine oxidase, and some suspecting both may be involved. Enzymatic N-acetylation, as well as O-demthylation of the methoxy groups have also been demonstrated, but these are minor metabolic routes in humans.
The metabolism of 2C-B (2,5-dimethoxy-4-bromophenethylamine) has been studied both by in vitro studies with rat livers and by analyzing urine samples from humans who had used the drug. In addition to some unchanged 2C-B, metabolites included 2,5-dimethoxy-4-bromophenylacetic acid, 2,5-dimethoxy-4-bromobenzoic acid, and 2-methoxy-5-hydroxy-4-bromophenethylamine. By comparing this data to what is known about mescaline metabolism, it seems likely that 2C-B follows a similar metabolic pathway.
Extrapolating from this, it seems likely that much 2C-T-2 and 2C-T-7 may be excreted unchanged, with oxidative deamination being the main metabolic pathway for the remainder. This would produce 2,5-dimethoxy-4-ethylthiophenylacetic acid in the case of 2C-T-2, and 2,5-dimethoxy-4-propylthiophenylacetic acid in the case of 2C-T-7. Some of the drugs are also likely metabolized by other pathways such as O-demethylation or N-acetylation. One direction for future research which may prove interesting is to compare the metabolism of 2C-T-2 and 2C-T-7. There seems to be much wider range of responses to 2C-T-7 than for 2C-T-2, as was discussed under dosage considerations. This may be indicative of some difference in the metabolism of the two drugs.
[ 24 February 2003: Message edited by: Murple ]